← Back to All Filings

Edwards Lifesciences Director Sells $218k in Company Stock (EW)

Low SignificanceDecember 12, 2025 at 6:02:29 PM EST

Edwards Lifesciences Corp

$EW4CIK: 0001099800

Subscribe to track EW

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Edwards Lifesciences Director Sells $218k in EW Stock

Company: Edwards Lifesciences Corp (EW) Form: 4 | Filed: 2025-12-12 Significance: Low

Insider: STONE HEISZ LESLIE Title: Director

Transaction: • Type: Sell • Shares: 2,615 • Price: $83.41 • Value: $218,082 • Owned After: 30,948 shares

Key Insight: A director sold a small amount of stock, representing less than 8% of their direct holdings and a negligible fraction (0.0004%) of the company's market cap.

Market Context: This is a routine, low-value transaction for an insider at a large-cap company like Edwards Lifesciences ($50.08B market cap) and is unlikely to be market-moving.

Comprehensive Analysis

SEC Filing Analysis: Edwards Lifesciences Corp (EW)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director executed a small, routine sale of common stock valued at approximately $218k.
  • Market Impact: The transaction is immaterial, representing a negligible fraction of the company's market capitalization and shares outstanding, and is unlikely to influence the market.

Company Information

FieldValue
CompanyEdwards Lifesciences Corp
Ticker SymbolEW
CIK0001099800
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies

Insider Information

FieldValue
NameSTONE HEISZ LESLIE
CIK0001235408
Title/PositionDirector
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2025-12-12
Transaction CodeS (Open market or private sale of securities)
Security TypeCommon Stock
Shares Involved2,615
Price Per Share$83.4109
Total Value$218,082.49
Shares Owned After30,948
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$218,082.49
% of Market Cap0.0004%
Shares Transacted2,615
% of Shares Outstanding0.0004%
Post-Transaction Ownership30,948 shares (0.0053% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $50.08 billion, this $218k transaction is financially insignificant.
  • Ownership Concentration: The insider's sale reduced their holdings by approximately 7.8%. Their remaining stake of 30,948 shares constitutes a very small portion (0.0053%) of the total shares outstanding.
  • Transaction Significance: The sale is well below any threshold for significance. Both the value relative to market cap and the shares relative to total outstanding are negligible, indicating a routine transaction likely for personal financial management.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is too small to signal any meaningful change in insider sentiment or to have a tangible impact on the stock's supply and demand dynamics.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is a tiny fraction of the typical daily trading volume for EW.
  • Sentiment Indicator: Neutral. This type of small, routine sale by a non-executive director is common and does not typically influence investor sentiment.

Additional Context

Transaction Notes

  • Timing: The sale was executed and reported on the same day, indicating timely disclosure.
  • Special Circumstances: No 10b5-1 plan was mentioned in the filing. The sale appears to be a discretionary trade.
Topics:#SECFiling#InsiderTrading#EW#EdwardsLifesciences#Form4#InsiderSell#StockMarket#MarketAnalysis#Finance

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.